Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

DIGITAL CONTENT

2 NEWS #PharmaBuzz

media
2 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

9DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ab928, 2239273-34-6, Ab-928, Etrumadenant, 3-(2-amino-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1h-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile, Etrumadenant [usan]

Molecular Formula

C₂₃H₂₂N₈O

Molecular Weight

426.5 g/mol

InChI Key

BUXIAWLTBSXYSW-UHFFFAOYSA-N

FDA UNII

W0ZE0NT8IF

Etrumadenant is an orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon administration, etrumadenant competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of AB928 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.

1 2D Structure

Etrumadenant

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[2-amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile

2.1.2 InChI

InChI=1S/C23H22N8O/c1-14-15(11-24)6-4-8-17(14)18-10-19(28-22(25)27-18)20-13-31(30-29-20)12-16-7-5-9-21(26-16)23(2,3)32/h4-10,13,32H,12H2,1-3H3,(H2,25,27,28)

2.1.3 InChI Key

BUXIAWLTBSXYSW-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N

2.2 Other Identifiers

2.2.1 UNII

W0ZE0NT8IF

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Ab928

2. 2239273-34-6

3. Ab-928

4. Etrumadenant

5. 3-(2-amino-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1h-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile

6. Etrumadenant [usan]

7. W0ze0nt8if

8. 3-[2-amino-6-[1-[[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-1h-1,2,3-triazol-4-yl]-4-pyrimidinyl]-2-methylbenzonitrile

9. Trumadenant

10. Unii-w0ze0nt8if

11. A2ar/a2br Antagonist-1

12. Etrumadenant [inn]

13. Etrumadenant [who-dd]

14. Chembl4740383

15. Schembl20401465

16. Gtpl11154

17. Bcp33220

18. Ex-a3172

19. Mfcd32263040

20. Nsc823658

21. S9608

22. Who 11620

23. Zb1610

24. Akos037649091

25. Ab928 ; Ab 928

26. Nsc-823658

27. Ac-36346

28. Bs-16547

29. Hy-129393

30. Cs-0105184

31. D81385

32. Q66977586

33. Benzonitrile, 3-[2-amino-6-[1-[[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-1h-1,2,3-triazol-4-yl]-4-pyrimidinyl]-2-methyl-

2.4 Create Date

2018-12-15

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₂N₈O
Molecular Weight	426.5 g/mol
XLogP3	1.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	5
Exact Mass	426.19165736 g/mol
Monoisotopic Mass	426.19165736 g/mol
Topological Polar Surface Area	139 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	680
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1